Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Post by: Diane De wyngaert in Immunic Press Release
Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States…
read more
17 Aug 2022
0

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén

Post by: Diane De wyngaert in Immunic Press Release
Immunic, Inc. Strengthens Its Board…
read more
07 Jul 2022
0

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Post by: Diane De wyngaert in Immunic Press Release
Immunic Announces Start of Patient…
read more
05 May 2022
0

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

Post by: Diane De wyngaert in Immunic Press Release
– Initiated Enrollment in Phase…
read more
24 Feb 2022
0

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

Post by: Diane De wyngaert in Immunic Press Release
- Unblinded Data Established a…
read more
14 Dec 2021
0

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

Post by: Diane De wyngaert in Immunic Press Release
NEW YORK, Dec. 9, 2021…
read more
10 Dec 2021
0

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

Post by: Diane De wyngaert in Immunic Press Release
NEW YORK, Nov. 18, 2021…
read more
22 Nov 2021
0

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

Post by: Diane De wyngaert in Immunic Press Release
– Fully Enrolled Phase 2…
read more
04 Nov 2021
0

Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis

Post by: Diane De wyngaert in Immunic Press Release
  – Top-Line Data Expected…
read more
28 Oct 2021
0

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Post by: Geert in Immunic Press Release
NEW YORK, Oct. 14, 2021…
read more
15 Oct 2021
0